Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Immunology
Импакт фактор: 1.404 5-летний Импакт фактор: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472

Выпуски:
Том 40, 2020 Том 39, 2019 Том 38, 2018 Том 37, 2017 Том 36, 2016 Том 35, 2015 Том 34, 2014 Том 33, 2013 Том 32, 2012 Том 31, 2011 Том 30, 2010 Том 29, 2009 Том 28, 2008 Том 27, 2007 Том 26, 2006 Том 25, 2005 Том 24, 2004 Том 23, 2003 Том 22, 2002 Том 21, 2001 Том 20, 2000 Том 19, 1999 Том 18, 1998 Том 17, 1997 Том 16, 1996 Том 15, 1995 Том 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.70
18 pages

The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants

Risini D. Weeratna
Coley Pharmaceutical Group, Ottawa
Paul J. Payette
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa
Heather L. Davis
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa

Краткое описание

The development of mucosal vaccines for humans has been hindered by the lack of safe yet effective mucosal adjuvants. Bacterial toxins are commonly used as adjuvants in animal models, but they are too toxic for use in humans. A novel class of adjuvant is CpG DNA, which contains unmethylated CpG dinucleotides in particular base contexts (CpG motifs). CpG DNA is most often coadministered with antigen in the form of synthetic oligodeoxynucleotides (CpG ODN), which are made with a nuclease-resistant phosphorothioate backbone. The vast majority of studies using CpG DNA as adjuvant have been with parenteral delivery; recently, however, mucosal immunization with CpG DNA as adjuvant has also been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will highlight the recent uses of CpG DNA as an adjuvant at mucosal surfaces.


Articles with similar content:

Novel Strategies Using DNA for the Induction of Mucosal Immunity
Critical Reviews™ in Immunology, Vol.19, 1999, issue 4
Heather L. Davis, Michael J. McCluskie
Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Zhengrong Cui, Russell J. Mumper
Mucosal Immunization: A Review of Strategies and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Mohan N. Rathi, Hinal Patel, Chetan Yewale, Ambikanandan Misra
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta
Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Mandeep Kaur, Goutam Rath, Tarun Garg, Amit Kumar Goyal